Sign in
Taking people in United StatesPhase 4

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Key facts

Who runs it
Henry M. Jackson Foundation for the Advancement of Military Medicine
Where
Bethesda, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
54 people, planned
Started
12 Nov 2025
Expected to end
Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pfizer-BioNTech mRNA COVID-19 vaccine
  • Novavax recombinant protein vaccine
Record updated
2 November 2026

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • 18-79 years old
  • Have a history of any of the following risk factors for severe COVID:; Current:; Age > 65 years old; Physical inactivity (defined as <150 mins of moderate activity per week or <75 mins of vigorous activity per week); HIV with CD4 count ≥ 500 cells/ul; Smoker; Obesity with BMI ≥ 30 and < 40; History of:; Asthma; Depression or other mood disorder; Schizophrenia spectrum disorder; Cerebrovascular disease; Heart failure; Coronary artery disease; Cardiomyopathy; Pulmonary embolism; Pulmonary hypertension; Cystic fibrosis; Bronchiectasis; Chronic obstructive pulmonary disease; Interstitial Lung Disease; Stage I or II chronic kidney disease (Stage 1 defined as normal GFR (> 90) but with other signs of kidney damage such as proteinuria or hematuria) (Stage 2 defined as having a glomerular filtration rate (GFR) of 60 - 89 ml/min/1.73m2); Gestational diabetes; Type 1 diabetes with most recent HgbA1C < 7.5%; Type 2 diabetes with most recent HgbA1C < 7.5%; Liver disease without cirrhosis and with liver enzyme levels (AST and ALT) no greater than three times the upper limit of normal; Smoking
  • Military Health System beneficiary and DEERS eligible
  • Willing to be randomized to receive either the Novavax COVID-19 vaccine or the mRNA Pfizer-BioNTech COVID-19 vaccine
  • Will be able to return for a clinic visit in approximately 30 days, Day 150, and be able to follow-up online for the next 9 months

Who cannot take part

  • Received a COVID-19 vaccine in the last 3 months
  • Active use of immune modulating medications; Defined as active use of chronic immune modulating medications such as systemic corticosteroids at a dose equivalence of 20 mg prednisone or greater daily for over one month, chemotherapy, cytokine inhibitors, or agents that reduce T cell or B cell numbers or function
  • Diagnosed with immunocompromised stated; Defined as: presence of a disease that is actively causing severe immune suppression or history of prior splenectomy (removal of spleen)
  • History of severe allergy or severe adverse reaction such as myocardial inflammation to any component of the mRNA COVID-19 vaccines or the Novavax recombinant COVID-19 vaccine
  • Tested positive for COVID-19 in the past 3 months; Presence of fever, cough, chills, shortness of breath, runny nose, or sore throat today on day of screening/enrollment visit
  • Diabetes with the most recent HgbA1C ≥ 7.5
  • Stage III or greater chronic kidney disease; Defined as estimated glomerular filtration rate < 60 ml/min/1.73m2)
  • History of solid organ or bone marrow transplant
  • Active malignancy; Defined as any cancer that is currently being treated or has shown evidence of progression within the past year
  • HIV with a CD4 cell count < 500 cells/ul
  • Chronic liver disease with compensated or decompensated cirrhosis, or liver enzyme levels (AST or ALT) greater than three times the upper limit of normal
  • Obesity with a BMI ≥ 40

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • Walter Reed National Military Medical CenterBethesda, United StatesContact: Irma BarahonaTaking people

About the trial

What the trial wants to find out

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

The 2 groups in the trial

  • For fall of 2026, Arm 1 of the study will be the Pfizer-BioNTech mRNA COVID-19 vacExisting treatment, for comparison

    Arm 1 of the study will be Pfizer-BioNTech mRNA COVID-19 vaccine

    Treatment: Pfizer-BioNTech mRNA COVID-19 vaccine

  • For fall of 2026, Arm 2 of the study will be the Novavax recombinant protein vaccineExisting treatment, for comparison

    Arm 2 of the study will be the Novavax recombinant protein vaccine

    Treatment: Novavax recombinant protein vaccine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Criteria questions
Built from NCT07287137, who can take part
Record updated
2 November 2026